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Abstract
In the present study, we examined the potential symptomatic and/or disease-modifying
effects of monthly bee venom injections compared to placebo in moderatly affected Parkin-
son disease patients. We conducted a prospective, randomized double-blind study in 40
Parkinson disease patients at Hoehn & Yahr stages 1.5 to 3 who were either assigned to
monthly bee venom injections or equivalent volumes of saline (treatment/placebo group:
n = 20/20). The primary objective of this study was to assess a potential symptomatic effect
of s.c. bee venom injections (100 μg) compared to placebo 11 months after initiation of ther-
apy on United Parkinson’s Disease Rating Scale (UPDRS) III scores in the « off » condition
pre-and post-injection at a 60 minute interval. Secondary objectives included the evolution
of UPDRS III scores over the study period and [123I]-FP-CIT scans to evaluate disease pro-
gression. Finally, safety was assessed by monitoring specific IgE against bee venom and
skin tests when necessary. After an 11 month period of monthly administration, bee venom
did not significantly decrease UPDRS III scores in the « off » condition. Also, UPDRS III
scores over the study course, and nuclear imaging, did not differ significantly between treat-
ment groups. Four patients were excluded during the trial due to positive skin tests but no
systemic allergic reaction was recorded. After an initial increase, specific IgE against bee
venom decreased in all patients completing the trial. This study did not evidence any clear
symptomatic or disease-modifying effects of monthly bee venom injections over an 11
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month period compared to placebo using a standard bee venom allergy desensitization pro-
tocol in Parkinson disease patients. However, bee venom administration appeared safe in
non-allergic subjects. Thus, we suggest that higher administration frequency and possibly
higher individual doses of bee venommay reveal its potency in treating Parkinson disease.
Trial Registration
ClinicalTrials.gov NCT01341431
Introduction
The cardinal motor symptoms of Parkinson disease (PD), akinesia, rigidity and rest tremor, are
due to degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc)
with subsequent depletion of dopamine in the striatum. This, in turn, modifies the activity of
basal ganglia output structures [1]. Therefore, symptomatic therapies in PD aim at either
repleting dopamine or normalising basal ganglia activity, for instance by high frequency deep
brain stimulation (DBS) of the globus pallidus internus (GPi) or the subthalamic nucleus
(STN). The holy grail, however, remains the development of neuroprotective strategies to slow
degeneration of nigral dopaminergic neurons and thus disease progression, at least with regard
to the motor triad. We propose that bee venom may exert both symptomatic and neuroprotec-
tive effects in PD.
Regarding potential neuroprotective effects of bee venom, hyperpolarization of midbrain
dopaminergic neurons resulting from blockade of Ca2+-activated small conductance K+ (SK)
channels by the bee venom toxin apamin partially rescues dopaminergic neurons from their
spontaneous demise in dissociated mesencephalic cultures [2]. Apamin is the only polypeptide
neurotoxin contained in bee venom to pass the blood-brain-barrier when injected peripherally
(18 aa peptide) and irreversibly blocks SK channels [3]. These channels (subtypes 1–3) are
present in various neuronal populations throughout the central nervous system and play a
major role in the control of the switch between tonic and burst firing in physiological condi-
tions [4]. SK3 channels can be detected on nigral dopaminergic neurons. Taken together, this
suggests that SK channel blockade of dopaminergic neurons not only controls their firing pat-
tern but ultimately, their survival [5].
Regarding the hypothesis that bee venom might exert acute, symptomatic effects on PD
motor symptoms, we suggest that these are not be due to striatal dopamine release only. In
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated (MPTP) mice [6] and 6-hydroxydopa-
mine-lesioned rats [7], bee venom and/or apamin raise striatal dopamine levels but the kinetics
of this increase are likely long-term as well as short-term. Therefore, a complementary option
is that blockade of SK channels downstream of the dopaminergic nigrostriatal system, i.e. on
basal ganglia relay or output nuclei may mediate motor effects. Indeed, SK2 receptors are pres-
ent on GABAergic substantia nigra pars reticulata (SNpr) and glutamatergic subthalamic
nucleus (STN) neurons [4], and bee venom restores the balance between inhibitory and excit-
atory influence exerted by the striatum and the STN on SNpr cells following dopaminergic
transmission interruption by neuroleptics injection, thereby normalising basal ganglia output
activity [8]. This effect is almost identical with that observed following DBS of the STN in rats
[9].
Several recent studies have adressed the potential use of bee venom therapy in PD models
and PD patients [6,7,8,10,11,12,13]. Based on these findings, we conducted a monocentric
Bee Venom and Parkinson Disease
PLOS ONE | DOI:10.1371/journal.pone.0158235 July 12, 2016 2 / 15
Competing Interests: Dr Hartmann hold parts on a
patent for the use of bee venom in the treatment of
Parkinson disease [https://register.epo.org/
application?number=EP08827269&tab=main/; https://
worldwide.espacenet.com/publicationDetails/
originalDocument?FT=D&date=20130122&DB=
EPODOC&locale=en_EP&CC=US&NR=
8357658B2&KC=B2&ND=5]. The main patent holder
is the APHP. He has received a travel grant from
Novartis, and received research support from "France
Parkinson"; Dr Habert received hononaria from GE
healthcare as a consultant and from PIRAMAL as a
speaker; Dr Kas received honoraria from Piramal
Pharmaceuticals for Reader Training session; Dr
Roze is the recipient of a grant "poste d'accueil" AP-
HP/CNRS. He received research support from
INSERM (COSSEC), AP-HP (DRC-PHRC),
Fondation pour la Recherche sur le Cerveau (FRC),
Merz-Pharma, Orkyn, IP santé, Ultragenyx; served
on scientific advisory boards for Orkyn,Ultragenyx
and Merz-pharma; received speech honorarium from
Merz-pharma, Novartis, Ipsen-Pharma and Orkyn,
received travel funding from Ipsen-Pharma, Teva,
Abbvie, Merz-Pharma, Dystonia Europe, the
Georgian Medical and Public Health Association the
International Federation of Clinical Neurophysiology,
and the Movement Disorders Society; Dr Degos
received research support from INSERM (COSSEC),
patient's association France Parkinson, received
travel fundings from Novartis, Teva, Lundbeck,
MERZ-pharma, received speech honorarium from
Novartis and Medtronic, and served on scientific
advisory boards for Aguettant; Dr Grabli is the
recipient of a grant "Contrat Interface" AP-HP/
INSERM. He received research support from AP-HP
(DRC-PHRC), France Parkinson; served on scientific
advisory boards for AbbVie; received speech
honorarium from UCB, Teva and Medtronic, received
travel funding from Teva, Novartis and Abbvie; Dr
Lacomblez received honoraria for clinical trials from
GSK, Trophos, Biogen; received grants from AFM,
ARSLA, Agence National pour la Recherche (ANR),
served on the scientific Advisory Board for Novartis,
received travel grants from Merck-Serono; Dr
Vidailhet has been an invited speaker at International
meetings (ENS, EFNS and MDS, COST dystonia
meetings) with refunds of travel expenses. She is on
the scientific advisory board of Merz and has been on
the advisory board of Novartis and Teva. She has
received unrestricted research grants from DHOS-
INSERM and ANR (French National Institutes) and
from AMADYS and Alliance France Dystonie (patient
associations); Dr Bonnet hold parts on a patent (see
link) for the use of bee venom in the treatment of
Parkinson disease. The main patent holder is the
APHP; Dr Corvol reports grants from the French
Ministry of Health, the Michael J. Fox Foundation,
double-blind, randomized controlled pilot study to evaluate the potential symptomatic and dis-
ease-modifying effects of monthly bee venom injections, as used in classic desensitization pro-
tocols against bee venom allergy, in moderately affected PD patients.
Methods
Patients
All clinical investigations were performed in accordance with the tenets of the Declaration of
Helsinki. All patients provided their written informed consent to participation. Our local insti-
tutional review board (Pitié-Salpêtrière Hospital, Paris/France) approved the aims and proce-
dures of the study (national reference number: 2009-016702-16; ClinicalTrials.gov reference:
NCT01341431). For the CONSORT checklist, please see S1 Fig.
Patients included suffered from PD as defined by the Parkinson’s Disease Society Brain
Bank [14]. They were over age 40 (to exclude young-onset PD forms), at Hoehn and Yahr
stages 1,5–3 during « off » periods, had a pathological [123I]-FP-CIT, an MRI excluding sec-
ondary or atypical forms of parkinsonism and had a negative skin test (ST) to bee venom.
Recruitment took place between April 2011 and June 2012 at the Department of Neurology,
Pitié-Salpêtrière Hospital, Paris/France.
Exclusion criteria were a Hoehn & Yahr stage<1,5 or>3, a secondary or atypical parkinso-
nian syndrome (verified clinically and by MRI), neuroleptic treatment within the last six
months except for domperidone, renal or hepatic insufficiency, abnormal ECG, normal [123I]-
FP-CIT, pregnancy or absence of contraception if in procreating age, non-treated major
depression or other severe psychiatric disorder according to DSM-IV-TR or cognitive
impairment (Mini Mental State (MMS)< 24/30). In addition, patients were not included if
they had a known allergy against bee venom or a contraindication against the use of pharma-
ceutical-grade bee venom (Alyostal1, Stallergenes, Antony, France), if ST against bee venom
was positive or if specific IgE antibodies against bee venom could be detected (>0.1 kU/L) at
the screening visit.
Study design
We performed a randomized, double-blind, placebo-controlled, parallel-group single-center
trial. Treatment was allocated according to a computer-generated randomization list in a 1:1
ratio. Randomization was performed via a central web-based system (http://randoweb.aphp.
fr). Patients were randomized into two groups and received either bee venom 100 μg (Alyos-
tal1) or placebo s.c. once a month over an 11 month periods (V2-V13). Depending on the
result of randomization and to maintain the blind, the pharmacy of the hospital prepared kits
containing either a syringe of bee venom (Alyostal1 100 μg in 1 mL of NaCl 0.9%) or a syringe
of placebo (NaCl 0.9%, 1 mL) that were identical in appearance. Then, these kits were labeled
with indications of research and patient identity, and were dispensed to the medical team for
each visit of administration.
For the conduction of ST, Alyostal1 was diluted in sterile saline solution containing 0.4%
phenol at a concentration of 0.1 μg/mL. Intradermal ST was done on the volar surface of the
forearm. Through a 25-gauge hypodermic needle, beginning with the highest dilution of bee
venom, 0.05 mL were injected. Prick ST with histamine (10 mg/mL) and phenol-saline diluent
solution were used as positive and negative controls, respectively. The reactions were read after
20 minutes. The cut-off value for a positive intradermal ST was a wheal diameter 6 mm asso-
ciated with a flare 10 mm and at least 70% of the histamine control [15] as well as a negative
response to the control phenol-saline solution.
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Serum IgE and IgG4 antibody measurements were performed using a fluorescence-immu-
noassay (CAP-FEIA) with commercially available total bee venom Immunocap and a Phadia
Unicap100 instrument, according to the manufacturer’s instructions (Thermo Fisher Scientific,
Waltham, MA). Isotype of the antibodies, IgE or IgG4, was determined with ImmunoCAP spe-
cific IgE conjugate and Immunocap specific IgG4 conjugate. Results were calculated in kU/L
for IgE antibodies and in mg/L for IgG4 antibodies. Limits of detection for IgE was 0.1 kU/L
and for IgG4 0.007 mg/L.
Patients were seen monthly after the pre-screening (V0) and selection (V1) visits. Subse-
quently, bee venom or placebo injections were performed over an 11 month period (V2-13)
and study participation ended with a final follow-up visit (V14). The United Parkinson’s Dis-
ease Rating Scale (UPDRS) [16] was performed in the « off » condition, before the first morn-
ing dose, after withdrawal of their levodopa treatment the evening before the visit. In case of
treatment with dopamine agonists, rasagiline or amantadine, treatments were stopped at least
five drug half-lives before evaluation. If necessary, equivalent doses of levodopa were adminis-
tered in the meantime to minimize patient discomfort.
We also used a segmental rating scale [17] which is likely more sensitive to change than the
UPDRS III. The segmental score was calculated as follows:
• The action and kinetic tremor score was the sum of all items for action and kinetic tremor
(but not rest tremor)
• For rest tremor rating always the worst tremor was rated. For rigidity rating, always the least
rigidity at rest was rated.
• The tremor severity score was the sum of all rest tremor items.
• The rigidity severity score was the sum of all rigidity items.
• The composite rigidity and tremor severity score was the sum of the tremor severity score and
the rigidity severity score.
Brain imaging
All patients underwent a brain MRI on a 3T MR unit (Siemens, Erlangen, Germany).
Sequences performed included a 3DT1 (sagittal plane acquisition, gradient echo sequence with
inversion recovery, 1 mm isotropic voxel), a 3DT2 (sagittal plane acquisition, fast spin echo
sequence, fast spin echo acquisition, 1 mm isotropic voxel) and an axial FLAIR (fluid attenu-
ated inversion recovery) sequence. Total acquisition time was 20 minutes. Images were ana-
lyzed by an experienced neuroradiologist (DG).
SPECT studies were performed in all subjects using a triple-head camera equipped with low
energy, high resolution parallel hole collimators (Irix, Philips), 3 hours after injection of 185
MBq (range 165–188 MBq) of [123I]-FP-CIT. Thyroid uptake was blocked before the scan by
administration of potassium perchlorate (400 mg orally). One hundred and twenty projections
were acquired for 30 minutes in a 128 x 128 matrix. Projections were reconstructed using an
iterative algorithm, post-filtered (low pass filter: order = 4, cut-off frequency = 0.35 cm-1), then
corrected for attenuation using the Chang method (μ = 0.12 cm-1) [18]. To ensure reproduc-
ibility between scans, patients were injected with the same dose (± 5%), with the same interval
between injection and acquisition, and same rotation radius to ensure similar resolution.
All reconstructed volumes were converted from DICOM to NIFTI format. Parametric
images of binding potential (BP) were computed from the reconstructed [123I]-FP-CIT vol-
umes using the Anatomist and Brainvisa software packages (http://brainvisa.info/). For each
Bee Venom and Parkinson Disease
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FP-CIT study, a volume of interest was drawn within the occipital cortex to obtain non-specific
activity, and BP was calculated in each voxel using the following formula: (mean voxel activity /
mean occipital activity) minus 1. The resulting parametric volumes were then spatially normal-
ized to the Montreal Neurological Institute (MNI) space with the Statistical Parametric Mapping
software (SPM8, Welcome Department of Cognitive Neurology, University College, London)
using a custom [123I]-FP-CIT template [19]. Next, BP was estimated for each parametric image
in a standard set of specific volumes of interest (VOI), i.e. right and left caudate nuclei, anterior
and posterior putamens, and whole striatum. These VOI were manually delineated on the MNI
single subject MRI. This method has been previously validated [19].
Safety assessment
The patients’ general health status (as reflected by body weight, systolic/ diastolic arterial blood
pressures, heart rate, electrocardiogram, and standard blood biochemistry profile) was assessed
every month. IgE testing was performed every two months. In case of significant rise of anti-
bodies, STs were repeated.
Objectives
The primary objective of this study was to assess a potential symptomatic effect of s.c. bee
venom injections (100 μg) compared to placebo 11 months after initiation of therapy (at V13)
on UPDRS III scores in the « off » condition pre-and post-injection at a 60 minute interval.
This choice was based on two hypotheses: (i) that a potential symptomatic effect would build
up over the study period; and (ii) that this effect would manifest itself 30–60 minutes, at latest,
after injection of bee venom.
Four secondary objectives were pre-specified as follows:
• Study the evolution of the symptomatic effect of bee venom along time (V2-13) as compared
to placebo on UPDRS III scores in the « off » condition at a 60 minute interval to verify
whether an effect might build up or vanish over time.
• Study the potential effect of monthly bee venom injections compared to placebo on disease
progression in the « off » condition by assessing UPDRS III scores between V2 and V13.
Dopaminergic treatment modifications over the same period were used as a concomitant
source of information on disease progression.
• Study the potential effect of monthly bee venom injections compared to placebo on disease
progression by dopaminergic denervation as assessed by [123I]-FP-CIT between V2 and
V13.
• Study the potential effect of monthly bee venom injections compared to placebo on motor
fluctuations by assessing UPDRS IV scores between V2 and V13.
Statistical analysis
Sample size was calculated assuming a mean of UPDRS III score before injection at visit 13
equal to 28 points, an improvement of 20% (i.e 5.6 points) after injection at visit 13 in the active
group without change in the placebo group and a standard deviation of 5.6 points in each arm.
To provide the study with a power of 80%, 40 patients had to be randomized. The sample size
was determined based on a 2-sided type I error rate of 5% using the Mann-Whitney test.
Bee Venom and Parkinson Disease
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The primary efficacy analysis was performed using the modified intent-to-treat (mITT)
population (defined as all randomized subjects who took at least one dose of study medication).
The primary criterion was missing for five patients in the bee venom arm (four positive ST dur-
ing the study period and one patient withdrawal). According to the protocol, these patients
were considered as failures with a variation of UPDRS III score after V13 equal to zero (no
improvement). The change in UPDRS III score between before and after injection at V13 was
compared with the Mann-Whitney test between the two groups. Change from baseline to V13
in UPDRS III score after each monthly injection was studied with a linear mixed model for
repeated measures included terms for treatment group, time and time by treatment interaction.
Change from baseline in UPDRS I, II and IV and in the segmental rating scale were also ana-
lyzed with a linear mixed model for repeated data. Changes from baseline in Parkinson’s dis-
ease questionnaire (PDQ)-39 summary index and in dopamine transporter binding potential
as assessed by [123I]-FP-CIT was compared between arms using the Mann-Whitney test. The
alpha level was set at 0.05 (two-sided). All analyses were performed with the SAS software ver-
sion 9.2 (SAS Institute, Cary, NC).
Results
Patient characteristics at baseline
Fifty patients diagnosed with PD were screened for participation in the trial. One subject had a
normal [123I]-FP-CIT, three had vascular lesions on MRI, three had positive IgE against bee
venom, one had cognitive deficits (MMS< 24/30) and two decided to not pursue the study
before randomization. Eventually, 40 patients were included into the study (Fig 1). Even if
patients who discontinued treatment and for which the primary outcome could not be col-
lected were excluded from the analysis, the difference between groups remained non-signifi-
cant (p = 0.68).
Twenty patients were included in the placebo arm (12 male, 8 female) and 20 patients in the
treatment (bee venom) arm (8 male, 12 female). Baseline demographic characteristics were
similar in both groups (Table 1). Although not significantly different between groups, it is
worth noting that patients in the bee venom group has lower UPDRS III scores and lower levo-
dopa-equivalent daily dose (LED) than their placebo counterparts, yet scored higher on the
UPDRS IV subscale.
Primary outcome
At V13, UPDRS III scores decreased both after placebo and bee venom injections (Table 2) and
the differences between the two groups were non-significant. With regard to disease progres-
sion, UPDRS III scores in the “off” state in both groups did not differ significantly over the
study period (Table 2). UPDRS I, II and IV scores did not change significantly between both
groups over the study period, nor did the total UPDRS scores (Table 2). Means and 95% confi-
dence intervals of differences compared to baseline for each visit are plotted in Fig 2.
Secondary outcomes
Both BREF (batterie rapide d'évaluation frontale) and MMS scores improved in the bee venom
compared to the placebo group between V2 and V13, albeit non-significantly (Table 2). No dif-
ferences were seen in change over time of Schwab and England scores and Hoehn and Yahr
stages (Table 2).
When comparing total PDQ-39 scores (Table 2), no significant differences could be noted
between the bee venom and placebo group over the study period. However, in the ADL
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(activities of daily living) subscale, patients in the bee venom group fared worse than those in
the placebo group (p = 0.05).
The assessment of tremor and rigidity using a segmental rating scale [17] showed no differ-
ence of evolution over the study period between the treatment groups in temporal or localiza-
tion scores. (Table 2). The maximal amplitude of rest tremor (p< 0.05) as well as action and
postural tremor (p< 0.02), however, decreased in the placebo group compared to controls.
Dopamine transporter imaging
Mean BP values in all regions of interest decreased between V1 and V13 in both groups consis-
tent with a progression of dopaminergic denervation along time. However, changes were not
significantly different between the two groups (Table 3).
Kinetics of bee venom specific IgE and IgG4
The 20 control patients and two patients out of 20 who received bee venom injections did not
produce either specific IgE or IgG4. The remaining 18 patients produced specific IgE, four
patients after the first bee venom injection (20%), five after the second (25%), and nine after
the third injection (45%). The peak of antibody synthesis was reached after the fifth injection
for half of the patients and then antibody concentration started to decrease (Fig 3A). Bee
Fig 1. Study Flowchart.
doi:10.1371/journal.pone.0158235.g001
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venom specific IgG4 were detected in 12 patients out of 20 (60%). However, specific IgG4 were
not determined in all samples of each patient. The kinetics of antibody production were avail-
able for six patients: three (50%) produced antibodies before the sixth injection and the remain-
der (50%) thereafter. The production of IgG4 antibodies was delayed an average of three
months to that of IgE antibodies, and was correlated with a decrease of the latter (Fig 3B).
Safety/tolerance / adverse effects
We classified four adverse events as severe, namely positive ST in patients treated with bee
venom and which led to their exclusion from the trial, one at V6, one at V7 and two at V8.
However, it must be noted that this was purely a precautionary measure as we never observed
anything corresponding to an allergic reaction. Other than that, we recorded the following
light adverse effects: redness/itching at the injection site (placebo: 6 / bee venom: 165), insom-
nia (placebo: 1 / bee venom: 1), nausea (placebo: 9 / bee venom: 3), fatigue (placebo: 10 / bee
venom: 2), dyskinesia (placebo: 1 / bee venom: 1), bradycardia (placebo: 2 / bee venom: 0).
Discussion
After an 11 month period of monthly administration, a single injection of bee venom did not
significantly decrease UPDRS III scores in the « off » condition. Also, UPDRS III scores over
the course of 11 months, and nuclear imaging, did not evolve significantly differently between
both treatment groups. LED increased less in the bee venom group compared to placebo but
again, differences between both groups failed to reach significance. Finally, motor fluctuations
and dyskinesia remained unaffected by bee venom treatment over the study period.
Table 1. Baseline characteristics in the placebo / bee venom groups.
Placebo (Median ; Interquartile
range)
Bee venom (Median ; Interquartile
range)
Age (years) 63.3 ; 8 60.3 ; 15
Time since diagnosis (years) 5.6 ; 4 5.9 ; 4.4
Time since ﬁrst symptoms
(years)
6.3 ; 5.1 6.2 ; 5
BREF 17 ; 0.5 17 ; 1.5
MMS 30 ; 2 29 ; 2
UPDRS I 1 ; 1 1 ; 2
UPDRS II 10.5 ; 7 9.5 ; 5
UPDRS III (off) 29 ; 16 25 ; 11
UPDRS IV 3; 2.5 3.5; 3.5
Schwab and England scores
- 70 2 (10%) 0
- 80 13 (65%) 9 (45%)
- 90 4 (20%) 9 (45%)
- 100 1 (5%) 2 (10%)
Hoehn and Yahr stages
- 2 7 (35%) 6 (30%)
- 2.5 11 (55%) 14 (70%)
- 3 2 (10%) 0
PDQ-39 –summary index 22.6; 20 24.7 ; 12.7
LED 512 ; 450 391 ; 306
doi:10.1371/journal.pone.0158235.t001
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One other clinical study has investigated the potential symptomatic effect of bee venom on
PD symptoms [13]. Using bee venom acupuncture twice a week for eight weeks at 10 acupunc-
ture points (compared to an acupuncture group without bee venom and a control group), a sig-
nificant decrease of UPDRS III scores from 15.0 to 10.0 points was observed (17.0 to 13.0 in
the acupuncture group, n = 13, p<0.05; 13.0 to 13.0 in the control group, n = 9). However, this
study is hardly comparable to ours as it remains unclear to what extent acupuncture and bee
venom contributed respectively to this effect. Also, the quantities of bee venom used were not
quantified in micrograms (0.01 mL bee venom diluted to 0.005% at each injection point) and it
thus remains unclear how much product was actually injected.
Cognition as assessed by the MMS appeared to be slightly enhanced under bee venom but
not significantly compared to placebo. Although the MMS is a rough tool to investigate cogni-
tive function, it is interesting to note that hippocampal SK channel blockade has been suggested
to enhance cognitive performance [20–22]. Recently, in 6-OHDA-lesioned rats, apamin i.p.
has been shown to display pro-cognitive effects, in addition to reversing motor deficits and
attenuating anxiety-related behavior [7].
Table 2. Main results in the placebo / bee venom groups.
Placebo Bee venom P-
value
Primary criterion
UPDRS III at V13: variation after injection
- Median, Interquartile range 1 ; 4.5 1 ; 2 0.86
- Mean, standard deviation 0.35 ; 2.85 0.72 ; 2.37
Change over time from V2 to V13 for criteria monthly
evaluated*
UPDRS III before injection - 0.11 (0.08) -0.03 (0.08) 0.23
UPDRS I before injection -0.03 (0.02) -0.015
(0.018)
0.67
UPDRS II before injection -0.087 (0.04) 0.013 (0.04) 0.08
UPDRS IV before injection 0.009 (0.02) - 0.023 (0.02) 0.32
Hoehn and Yahr stages -0.0009
(0.0001)
-0.0007
(0.0001)
0.3
Schwab and England scores 0.005 (0.003) -0.001
(0.003)
0.09
Variation between V14 and V1 for criteria evaluated at the
inclusion and at the end of study
BREF
- Median, interquartile range 0 ; 1 0 ; 0.5 0.22
- Mean, standard deviation 0 ; 1.5 -0.2 ; 1
MMS
- Median, interquartile range 0 ; 2 0 ; 1 0.13
- Mean, standard deviation - 0.2 ; 1.6 0.7 ; 1.04
LED
- Median, interquartile range 51 ; 129 0 ; 162.7 0.22
- Mean, standard deviation 98; 156 64 ; 127
PDQ-39
- Median, interquartile range -1.5 ; 9.2 2.2; 13.5 0.6
- Mean, standard deviation -1.2 ; 5.4 -0.3; 7.5
* Data are presented with estimates of monthly variation and its standard error (regression parameters of the
linear mixed model for repeated data)
doi:10.1371/journal.pone.0158235.t002
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Fig 2. Evolution of the differences of UPDRS III (A), II (B) and total scores (C) with baseline over the 11
month study period in the placebo and bee venom groups.
doi:10.1371/journal.pone.0158235.g002
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Surprisingly, the ADL subscores on the PDQ-39 scale improved significantly over the study
period in the placebo group compared to the bee venom group. We can only speculate about
the reasons for these changes given that they do not correlate with motor scores. Most likely,
the local inflammatory reactions frequently observed after bee venom injections may contrib-
ute to this effect. As such, they were generally not debilitating but nonetheless anxiogenic since
patients usually wished to know whether these reactions were due to bee venom or not, a ques-
tion we were of course unable to answer during the study period due to blinding.
The decrease of amplitude of rest, positional and action tremor using the segmental rating
scale in the placebo group was equally unexpected. At baseline, patients in the placebo group
had more severe postural and kinetic tremor than those who were to be treated with bee
venom. We suppose that the difference at the end of the study between the groups is partly due
to a floor effect among patients who received bee venom and had milder tremor. In addition to
more severe positional and kinetic tremor, at baseline control patients had higher Hoehn and
Yahr stages, higher UPDRS III ratings, higher LED, lower scores on the Schwab and England
scale, and a longer duration of manifest PD. We therefore think that patients in the control
group were slightly more affected. Possibly as a consequence, LED showed a trend towards
higher increase over the study period among control patients.
Regarding safety, despite the production of specific IgE antibodies in response to bee venom
injection, no clinical symptoms of allergy were detected. The protocol we used seems safe and
was consistent with the highest dose recommended by the manufacturer for immunotherapy,
100 μg in a single injection. About 45% of patients produced IgE before the third injection and
the remainders after. The peak of IgE synthesis was observed after the fifth injection in half of
patients and IgG4 production began subsequently to be detected in half of patients after the
sixth injection. Thus, early in the immune response a critical phase may exist which may cause
allergy with clinical symptoms. However, over time, a balance in the level of specific IgE and
IgG4 antibodies is induced. This phenomenon explains the desensitization of allergic patients
treated by immunotherapy and may also put to rest fears of using bee venom in non-allergic
subjects, which is a important finding as such and paves the way for future studies.
This study has several limitations. First, because of safety concerns, we stuck to a typical
desensitization protocol for allergies against bee venom. To achieve more potent effects of bee
venom, it is likely necessary to increase the dosage and/or to decrease the injection interval, for
instance to at least fortnightly or even weekly injections. In traditional apitherapy with live
bees (personal communications), patients are treated weekly or bi-weekly with up to four stings
per session which makes for a comparative dose 16 times higher than the one used in our
study. Also, in a randomized cross-over trial of bee stings in multiple sclerosis, patients were
stung by up to 20 bees three times per week, pushing the comparative dose to 90 times that
used in our study [23]; note that in this study, no allergic reactions occurred in the 25 patients
who completed the trial over a 6 month period. However, no routine IgE monitoring or STs
were performed. Finally, in our own MPTP mouse study, bee venom was administered twice
Table 3. Comparison of [123I]-FP-CIT binding potential changes between V2 and V13 in the placebo / bee venom groups.
Region Placebo (mean ± standard deviation) Bee venom (mean ± standard deviation) P-value
Caudate (right hemisphere) -0.111 ± 0.194 -0.093 ± 0.193 0.56
Caudate (left hemisphere) -0.121 ± 0.210 -0.079 ± 0.188 0.41
Anterior putamen (right hemisphere) -0.115 ± 0.215 -0.108 ± 0.206 0.97
Anterior putamen (left hemisphere) -0.062 ± 0.138 -0.037 ± 0.198 0.62
Posterior putamen (right hemisphere) -0.019 ± 0.163 -0.067 ± 0.170 0.62
Posterior putamen (left hemisphere) -0.026 ± 0.202 -0.010 ± 0.194 0.99
doi:10.1371/journal.pone.0158235.t003
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Fig 3. Kinetics of bee venom specific antibodies. The sample at day -60 was taken at the pre-screening, the first bee venom injection was done at day 0
and the first sample after at day 30. Diamonds are for specific IgE (kU/L) and the squares for specific IgG4 (mg/L). (A)kinetics of specific IgE production for
all patients; (B) kinetics for specific IgE and IgG4 for a single representative patient.
doi:10.1371/journal.pone.0158235.g003
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weekly with dosages of 120 μg/kg body weight, thereby ranging up to 100 times higher than in
humans [6]. Second, based on the observed results, the study was underpowered. When we
planned the study, we overestimated the difference between groups. The observed size effect
was 0.14 while we planned the study with a size effect equal to one. Regarding drop outs, it
must be underlined that these patients were excluded based on very and possibly overly strict
safety concerns (see above) as no allergic reactions actually occurred. However, to avoid any
preventable risk, we decided to be extremely conservative in our exclusion policy. Third and
lastly, patients in the bee venom group were less severely affected than the patients in the pla-
cebo group, which might have distorted/diminished possible treatment effects.
As bee venom is a potentially lethal substance in case of an anaphylactic reaction, two
options appear feasible to design a safer substance: first, to use apamin as a monotherapy.
However, apamin is currently not licensed for any medical condition and would therefore have
to undergo phase I toxicology testing before a phase II trial could be considered. Of note, ani-
mal data suggest that the therapeutic range of apamin may be narrower as a single substance
than when embedded in whole bee venom. In MPTP-treated mice, high dose apamin treatment
induced motor symptoms akin to tremor or dyskinesia [6]. In SK3-deficient mice, symptoms
reminiscent of psychosis could be observed [24]. Also, apamin seemed to induce less neuropro-
tective effects than whole bee venom in our mouse study, suggesting that other components of
bee venom might contribute to this effect [6]. One candidate, for instance, is mellitin which has
been shown to slow motor neuron degeneration in a murine amyotrophic lateral sclerosis
model [25]. Therefore, an alternative strategy might be to remove the allergens from bee
venom. The most potent allergens in bee venom is phospolipase A2, followed by hyaluronidase
and icarapin [26]. Also, weaker allergens such as mellitin or ingredients whose allergenicity
remain unknown (vitellogenin) are present in bee venom [26]. Thus, allergen removal is proba-
bly a challenging process. Moreover, it cannot be excluded that these also contribute to poten-
tial symptomatic and/or neuroprotective effects of bee venom [27].
In summary, our study did not evidence any clear symptomatic or disease-modifying effects
of monthly bee venom injections over an 11 month period compared to placebo using a stan-
dard bee venom allergy desensitization protocol in PD patients. Of note, bee venom adminis-
tration appeared safe in non-allergic patients. Given the increasingly strong preclinical
rationale that SK channel blockade may be beneficial in treating PD short and long term, we
believe that a larger study with less stringent exclusion criteria regarding IgE levels and ST is
warranted. In particular, we feel that higher administration frequency and possibly higher indi-
vidual doses of bee venom may reveal its potency in treating PD.
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